Shire Regenerative Medicine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://abh.com
Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Phase 3
Completed
- Conditions
- Venous Leg Ulcer
- Interventions
- Device: DermagraftDevice: Profore
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Shire Regenerative Medicine, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT01891760
- Locations
- 🇺🇸
Dr. Jagpreet S. Mukker, Fresno, California, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Stony Brook University Medical Center, Stony Brook, New York, United States
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
Phase 3
Terminated
- Conditions
- Epidermolysis Bullosa
- Interventions
- Other: Control wound treatmentBiological: ABH001
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Shire Regenerative Medicine, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT01749306
- Locations
- 🇦🇹
Landeskrankenhaus Salzburg-Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Rady Children's Hospital - San Diego/UCSD, Pediatric and Adolescent Dermatology, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath